Entropy Neurodynamics wins ethics approval for 72-patient TRP-8803 basket trial
Reuters2026/08/04 14:00- Entropy Neurodynamics secured Human Research Ethics Committee clearance to start a Phase 1b/2a basket trial of TRP-8803, an IV psilocin therapy.
- The open-label study targets 72 patients across eight indications to speed indication selection and support commercialization planning.
- Swinburne University signed a clinical trial research agreement to help run the program; first dosing is expected later this quarter.
- Budget set at about AUD 3.2 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AirAsia says drug tests for all active pilots, cabin crew return negative results
GE HealthCare (GEHC.US) plans to acquire Sofie for $1 billion, aiming for high growth in the radiopharmaceutical sector
GE Healthcare plans to acquire Sofie for about $1 billion, aiming to expand recurring revenue by combining imaging devices with radiodiagnostic agents, in response to weak stock performance and pressure from activist investors.
Silver Price Forecast: XAG/USD bears have the upper hand below $64.75-$64.85 confluence
Resonac Holdings says RESONAC REPORT 2026 integrated report now available
Crypto prices
More
